"Express Mail" Label No. EV 330860085U5

Date of Deposit February 2, 2004

Attorney Docket No.: 018512-003814US

This is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Grant Andrew McNaughton-Smith, et al.

Continuation of Application

No.: 10/004,122

Filed: November 1, 2001

For: BENZANILIDES AS POTASSIUM

CHANNEL OPENERS

Examiner: Davis, Z.

Art Unit: 1625

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and

§1.98

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 10/004,122, filed 11/01/01 (Attorney Docket No. 018512-003813US) and Application No. 09/632,576, filed August 4, 2000 (Attorney Docket No. 018512-003810US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Grant Andrew McNaughton-Smith, et al. Continuation of Application No.: 10/004,122 Page 2

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Kenneth E. Jenkins, Ph.D.

Reg. No. 51,846

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

KEJ:kad 60095079 v1

Substitu	ite for form 1449A/PT	0		Complete if Known		
				Application Number	Continuation of 10/004,122	
INFO	ORMATION	l DI	SCLOSURE	Filing Date	November 1, 2001	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	McNaughton-Smith, Grant A.	
				Art Unit	1625	
	(use as many sh	eets a	s necessary)	Examiner Name	Davis, Z.	
Sheet	1	of	2	Attorney Docket Number	018512-003814US	

			U.S. PATENT DO	CUMENTS+							
	Document Number										
Examiner Initials*	Cite No. ¹	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear						
	AA	US 5,466,698 A	11/14/1995	Glase, et al.							
	AB	US-									
	AC	US-									
·	AD	US-									
	AE	US-	- = 1								

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document				Name of Patentee or	Pages, Columns, Lines, Where Relevant		
		Country Code ³	Number⁴	Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T⁵	
	AF	DE	2343787	A1	03-21-1974	Sterling Drug Co.			
	AG	JP	57-131719	A2	08-14-1982	Chugai Pharm.			
	AH	JP	57-206661		12-18-1982	Chugai Pharm.			
	Al	JP	58-069812	A2	04-26-1983	Chugai Pharm.			
	AJ	JP	181257	A2	10-15-1984	Chugai Pharm.			
	AK	DE	3305569	A1	08-23-1984	Bayer, A.G.			
	AL	JP	59-175467	A2	10-04-1984	Chugai Pharm.			
	АМ	DE	3804346	A1	08-24-1989	Boehringer Mannheim GmbH			
	AN	JP	10-259176		12-09-1998	Eli Lilly and Co.			
	BA	EP	882,726	A1	12-09-1998	Eli Lilly and Co.			
	ВВ	wo	98/37068	A1	08-27-1998	Bristol-Myers Squibb			
	вс	wo	98/42672	A1	10-01-1998	Kyowa Hakko Kogyo Co. Ltd.			
	BD	wo	99/05113		02-04-1999	BYK Gulden Lomberg Chemische Fabrik GMBH			

Examiner Signature	Date Considered	

Substitute t	for form 1449B/PT()	-	Complete if Known		
INFO		DIC	CLOCUDE	Application Number	Continuation of 10/004,122	
· ·			CLOSURE	Filing Date	November 1, 2001	
STAT	EMENT B	ΥA	PPLICANT	First Named Inventor	McNaughton-Smith, Grant A.	
				Art Unit	1625	
(use as many sheets as necessary)				Examiner Name	Davis, Z.	
Sheet	2	of	2	Attorney Docket Number	018512-003814US	

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2					
	BE	Arakida, et al. "Binding of YM158, a new Dual Antagonist for Leukotriene D₄ and Thromboxane A₂ Receptors, to Guinea Pig Lung Membranes" European Journal of Pharmacology (1998) Vol. 362, pp. 229-233.						
	BF	Sawanishi, et al. "Studies on Diazepines, XXVI. Synthesis of 6H-1,4-diazepines and 1-Acyl-1-H-1,4-diazepines from 4-pyridyl azides" <i>Chem. Pharm. Bull.</i> (August 1987) Vol. 35(8), pp. 3175-3182.						
	BG							
	ВН							

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.